ACSBG2

Across TCGA pan-cancer cohorts, ACSBG2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ACSBG2 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ACSBG2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACSBG2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

LSCC, LUAD, and UCEC are the cancer types where ACSBG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.324	0.806	.001	18	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	8	view →
UCEC	OS	Quartile	All	1.000	0.829	.019	6	view →
HNSC	OS	Median	III,IV	0.484	1.000	.038	4	view →
PDAC	OS	Median	All	0.486	0.659	.022	3	view →
CCRCC	DFS	Quartile	All	1.000	0.836	.006	3	view →
GBM	OS	Quartile	All	0.674	0.399	.007	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ACSBG2–LSCC (DFS)

Open the LSCC breakdown →